Literature DB >> 10809223

Mucosal melanomas: a review.

J G Batsakis1, P Suarez.   

Abstract

Mucosal melanomas, far fewer in number than melanomas of the skin, manifest a far more aggressive and more rapid life-consuming biologic course. This behavior attends melanomas at any mucosal site, upper aerodigestive tracts, anorectum, and male and female genital tracts. Prognostic factors for both groups of melanoma are similar, but most mucosal melanomas have reached the dangerous limits, e.g., depth of invasion or thickness of melanoma at the time of diagnosis. In general, the mucosal melanomas are also more refractory to therapeutic modalities. In part, this may be due to anatomic restrictions of site and the large size of tumor when first discovered. This review presents a contemporary assessment of melanomas at all of the major mucosal sites.

Entities:  

Mesh:

Year:  2000        PMID: 10809223     DOI: 10.1097/00125480-200007030-00006

Source DB:  PubMed          Journal:  Adv Anat Pathol        ISSN: 1072-4109            Impact factor:   3.875


  12 in total

1.  Primary nasolacrimal duct malignant mucosal melanoma.

Authors:  A M Lewis; P M Clarke; J M Olver
Journal:  Br J Ophthalmol       Date:  2006-01       Impact factor: 4.638

2.  [Malignant head and neck melanoma : Part 1: Diagnosis and histological particularities].

Authors:  C Pföhler; T Vogt; C S L Müller
Journal:  HNO       Date:  2015-07       Impact factor: 1.284

3.  Metastatic malignant melanoma of the small bowel--report of two cases.

Authors:  Shirley Sundersingh; Urmila Majhi; Senthil Kumar A Chandrasekar; Ramakrishnan A Seshadri; Suresh Kumar Dakshinamurthy; Kathiresan Narayanaswamy
Journal:  J Gastrointest Cancer       Date:  2012-06

4.  Unexpected Long Survival in Primary Malignant Melanoma of the Male Urethra.

Authors:  Evi Comploj; Salvatore Palermo; Emanuela Trenti; Michele Lodde; Christine Mian; Rodolfo Carella; Armin Pycha
Journal:  Case Rep Dermatol       Date:  2009-11-20

5.  From melanocyte to metastatic malignant melanoma.

Authors:  Bizhan Bandarchi; Linglei Ma; Roya Navab; Arun Seth; Golnar Rasty
Journal:  Dermatol Res Pract       Date:  2010-08-11

Review 6.  [Anorectal melanoma. A rare and highly malignant tumor entity of the anal canal].

Authors:  B M Helmke; H F Otto
Journal:  Pathologe       Date:  2004-05       Impact factor: 1.011

7.  Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.

Authors:  F Stephen Hodi; Christopher L Corless; Anita Giobbie-Hurder; Jonathan A Fletcher; Meijun Zhu; Adrian Marino-Enriquez; Philip Friedlander; Rene Gonzalez; Jeffrey S Weber; Thomas F Gajewski; Steven J O'Day; Kevin B Kim; Donald Lawrence; Keith T Flaherty; Jason J Luke; Frances A Collichio; Marc S Ernstoff; Michael C Heinrich; Carol Beadling; Katherine A Zukotynski; Jeffrey T Yap; Annick D Van den Abbeele; George D Demetri; David E Fisher
Journal:  J Clin Oncol       Date:  2013-06-17       Impact factor: 44.544

8.  Mucosal malignant melanoma of sino-nasal region with orbital involvement: case report.

Authors:  Jain Shraddha; Madhu Priya; Kumar Sunil
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2012-01-06

9.  Primary penile melanoma with an incidental renal oncocytoma.

Authors:  Louise Catherine McLoughlin; Niall F Davis; Adrian Cham; Ponnusamy Mohan
Journal:  BMJ Case Rep       Date:  2013-09-12

10.  Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma.

Authors:  Katherine Zukotynski; Jeffrey T Yap; Anita Giobbie-Hurder; Jeffrey Weber; Rene Gonzalez; Thomas F Gajewski; Steven O'Day; Kevin Kim; F Stephen Hodi; Annick D Van den Abbeele
Journal:  Cancer Imaging       Date:  2014-11-12       Impact factor: 3.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.